3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
5
Terminated
4
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Plasma cell
1
Conditions
Waldenstrom Macroglobulinemia
1
Multiple Myeloma
1
Interventions
Dexamethasone
20
daratumumab
17
Bortezomib
12
Lenalidomide
11
pomalidomide
8
Cyclophosphamide
8
Calcium Dobesilate
7
belantamab mafodotin
5
isatuximab
4
fludarabine
4
carfilzomib
4
Melphalan
4
dexamethasone acetate
3
dexamethasone 21-phosphate
3
auricularum
3
Specimen Handling
3
Biopsy
3
tocilizumab
2
iberdomide
2
Stem Cell Transplantation
2
Maintenance
2
Injections
2
Immunotherapy, Adoptive
2
Hyaluronoglucosaminidase
2
Fluorodeoxyglucose F18
2
Exercise Therapy
2
Drug Therapy
2
CT103A chimeric antigen receptor
2
zanubrutinib
1
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
ibrutinib
×
Plasma cell
×
Clear all
NCT07474961
2026-03-16
BLOOD-dose
Rigshospitalet, Denmark
Phase 4
Not yet recruiting
400 enrolled